Table 1

Serum BAFF levels and BAFF-R expression on CD19+ B cells

BAFF (ng/ml) median (range)Naive B cells CD19+ CD27− (%) median (range)Memory B cells CD19+ CD27+ (%) median (range)
NC (n:11)0.88 (0.68–1.03)98.4 (95.7–99.8)88.3 (77.3–95.8)
Pre-RX (n:15)1.09 (0.69–1.89)97.8 (71.7–99.7)87.3 (69.3–97.1)
C-R (n:13)3.03**# (1.31–7.09)90.3** (58.6–98.6)54.8****## (23.4–82.1)
D-R (n:11)2.55**# (1.02–7.46)85.4***# (57.7–97.6)55.8****### (27.4–77.6)
D-NR (n:5)2.25* (1.11–4.13)98.3 (88–99.7)79.3 (64.1–96.9)
  • * p<0.05;

  • ** p<0.01;

  • *** p<0.001;

  • **** p<0.0001 compared with normal controls (NC) (Mann–Whitney).

  • # p<0.01;

  • ## p<0.001;

  • ### p<0.0001 compared with pre-B-cell depletion therapy.

  • BAFF, B cell-activating factor; C-R, concordant clinically relapsing; D-NR, discordant clinically non-relapsing; D-R, discordant clinically relapsing; pre-RX, prerituximab.